NCT06761066 · NOT YET RECRUITING
Efficacy and Safety of NVP-NK4146 in Patients with Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
This trial is testing a dietary supplement called NVP-NK4146 against a placebo in adults aged 60 and older who have mild cognitive impairment (MCI) with confirmed amyloid buildup in the brain. Researchers want to see whether the supplement helps cognition and is safe. This is a Phase NA study, meaning it is exploratory in nature — early-stage evidence gathering, not a proven or approved treatment.
You may qualify if
- Male and female adults aged 60 or older
- Subject who meet the National Institute of Aging and Alzheimer's Associations (NIA-AA) core clinical criteria for MCI and have positive readings from amyloid PET
- Subject who can read and understand the Informed Consent Form and legends and who voluntarily decided to participate in current clinical trial and have signed the Informed Consent Form
You're excluded if
- Subject diagnosed with dementia according to the criteria of DSM-5 or ICD-10
- Subject currently receiving treatment for malignant tumors (except those who have fully recovered from cancer for more than 5 years or those with basal cell carcinoma, squamous cell carcinoma, or prostate cancer may participate at the investigator's discretion)
- Subject who are illiterate and/or without any education
- Any other factors deemed by the investigator to be likely to ineligible for the study
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-01-13